Pfizer Inc. (PFE) Tuesday settled its litigation against Teva Pharmaceuticals USA Inc., a part of Teva Pharmaceuticals Ltd. (TEVA), relating to Pfizer's patent covering the use of Viagra to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).
As a result of the settlement, Teva will be allowed to launch a generic version of Viagra in the United States on December 11, 2017, or earlier under certain circumstances.
Teva will pay Pfizer a royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential.
Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Viagra.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.